Category Archives: Biotechnology

At the end of the latest market close, Vir Biotechnology Inc. (VIR) was valued at $50.43. In that particular session, Stock kicked-off at the price of $50.07 while reaching the peak value of $53.24 and lowest value recorded on the day was $49.85. The stock current value is $51.89.

Recently in News on August 20, 2020, Vir Biotechnology Presents Data on VIR-2218 from Clinical Studies for the Treatment of Hepatitis B at the EASL Digital International Liver Congress. Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that data from its VIR-2218 clinical program will be featured at the European Association for the Study of the Liver (EASL) Digital International Liver Congress from August 27-29, 2020. VIR-2218 is an investigational small interfering ribonucleic acid (siRNA) that mediates RNA interference (RNAi) for the potential treatment of chronic hepatitis B virus (HBV) infection and is the first investigational medicine from Virs partnership with Alnylam Pharmaceuticals, Inc. to enter clinical trials. You can read further details here

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology Inc. shares are logging -30.81% during the 52-week period from high price, and 345.39% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1039156 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology Inc. (VIR) recorded performance in the market was 312.64%, having the revenues showcasing 40.02% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 6.59B, as it employees total of 253 workers.

During the last month, 0 analysts gave the Vir Biotechnology Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 39.22, with a change in the price was noted +16.39. In a similar fashion, Vir Biotechnology Inc. posted a movement of +46.17% for the period of last 100 days, recording 1,365,983 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity The total Debt to Equity ratio for VIR is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Vir Biotechnology Inc. in the period of last 50 days is set at 86.05%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 67.97%. In the last 20 days, the companys Stochastic %K was 66.60% and its Stochastic %D was recorded 73.15%.

Bearing in mind the latest performance of Vir Biotechnology Inc., several moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 312.64%. The shares increased approximately by -1.63% in the 7-day charts and went down by 4.53% in the period of the last 30 days. Common stock shares were driven by 40.02% during last recorded quarter.

Read more from the original source:
Vir Biotechnology Inc. (VIR) Quarterly Performance is 40.02%: Here is the Surprise Factor - The InvestChronicle

Unity Biotechnology Inc (UBX) is around the bottom of the Biotechnology industry according to InvestorsObserver. UBX received an overall rating of 38, which means that it scores higher than 38 percent of all stocks. Unity Biotechnology Inc also achieved a score of 28 in the Biotechnology industry, putting it above 28 percent of Biotechnology stocks. Biotechnology is ranked 18 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 38 means the stock is more attractive than 38 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Unity Biotechnology Inc (UBX) stock is lower by -5.48% while the S&P 500 has gained 0.08% as of 3:44 PM on Thursday, Aug 20. UBX is lower by -$0.17 from the previous closing price of $3.20 on volume of 3,480,403 shares. Over the past year the S&P 500 is up 15.50% while UBX is lower by -51.29%. UBX lost -$1.86 per share the over the last 12 months.

To screen for more stocks like UBX click here.

Link:
Is Unity Biotechnology Inc (UBX) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Asia Green Biotechnology Corp. (AGB or the Company) (CSE:ASIA) is pleased to announce that it has entered an agreement with Pathway Rx Inc. (Pathway Rx) pursuant to which AGB is granted an exclusive license to clinically develop and commercialize the Cannabis sativa varieties to which Pathway Rx Inc. owns the rights for prevention and for treatment of COVID-19 and other infectious diseases. Both companies wish to see those varieties, and possibly other versions of the strains, studied for their efficacy in humans and eventually approved and applied as new drugs and as over-the-counter health products. This agreement grants a license to AGB to deploy the technology for the purpose of completing further research, development, testing and additional validation and establishment of practical applications with a view to commercialization of the technology in the greater region of Asia

The clinical developments and commercialization contemplated in the agreement include but may not be limited to the completion of the following steps:

a. Determination with Pathway Rx of the study design and endpoints most advantageous to the patient population, the international emergency, and the commercialization opportunity. The study design for treatment of COVID-19 will include pre-treatment and post-treatment of gut fauna and flora, drug-to-drug interaction prediction with Cytochrome P450 precision medicine genetic testing, pre-treatment and post-treatment of respiration and lung and major organ fibrosis, laboratory testing of each patient in the studies showing the inflammatory markers that predict the onset of the cytokine storm, laboratory testing using cannabis drug efficiency index software, and other important scientific markers of effectiveness of the treatment and scientific and medical information that may be of assistance in greater recovery for the patients health. Once appropriate approvals are obtained, initial phase testing is expected to commence in January, 2021 and extend over a period of approximately four months. Results from that phase will inform the decision on how next to proceed. In the process of obtaining those approvals Pathway Rx will determine whether the trials are conducted under the direction of the United States Food & Drug Administration (the FDA) or Health Canada.

b. Development of Pre-Investigational New Drug Applications and meeting with the FDA and Health Canada officials to request Emergency Use Authorizations for Phase II studies of 300 patients and controls, or more, and thereafter Emergency Use Authorizations for Phase III studies of 1,050 patients and controls, or more, to use the extracts to treat patients hospitalized for COVID-19 infection.

c. Provision for the cost and conduct of Phase II clinical studies which will include but not be limited to physician recruitment, patient recruitment, cost of cannabis extracts, patient monitoring, data analysis reporting and assistance with preparation of study results to be submitted to major scientific journals.

d. Provision for the cost and conduct of Phase III clinical studies to gain new drug approvals of the extracts and/or versions of the extracts.

e. Provision for any required Phase IV after-market studies, if required by either the FDA or Health Canada.

f. Provision of marketing and sales costs for strong distribution of the products in the licensed territories and elsewhere.

g. Provision for clinical studies to support marketing and sales of the developed novel Cannabis sativa varieties in the licensed territories and elsewhere through dermal patch technologies, gel caps, sublinguals, extract drops, suppositories, and as a nasal spray to prevent infection with COVID-19.

The agreement recognizes that Pathway Rx has entered a similar license agreement in respect of other territories with another independent corporation, and that the obligations of that third party corporation parallel those of the Company both in terms of payment obligations, royalty obligations and satisfaction of terms and conditions upon which the corresponding license is granted. AGB and Pathway Rx have commenced negotiations with that third party corporation for the purpose of jointly achieving the clinical testing and commercialization objectives set out herein. All three of those parties recognize that such an agreement will be beneficial relative to the achievement of those objectives.

Consideration payable by the Company to Pathway Rx includes royalties on commercial sale of derivative products in the licensed territories on a sliding scale. In addition, and to initiate and support commencement of the clinical studies processes contemplated by the agreement, the Company will make available $100,000 to Pathway Rx within 30 days from August 13, 2020 and a further $500,000 within 90 days of that date. In the event a third party corporation does not participate in the financing and completion of these studies, AGB has the option to assume the additional payment obligations and extend the license granted accordingly to include the balance of worldwide rights.

This agreement complements and is an adjunct to the agreement made with Swysh Inc. and announced on March 19, 2020 wherein AGB is participating in research and development activities based on Swyshs intellectual property and associated rights to control and market health, skin care and a variety of other products successfully derived from those activities.

Dr. Igor Kovalchuk, a director of AGB, is also the chief executive, a director and a shareholder of Pathway Rx and Swysh (controlling shareholder). As such, he will maintain an active and direct role in the initiation and ongoing administration of the clinical testing activity to be undertaken. To date, Dr. Kovalchuk and his partner, Dr. Olga Kovalchuk have, through Pathway Rx and Swysh, been the primary principals in the research and development activities undertaken in relation to the subject cannabinoid varieties. This research has resulted in the filing of a patent application with the United States Patent Office in respect of new and unique Cannabis sativa lines, extracts and methods for their use to inhibit the levels of ACE2 receptor in oral, lung and intestinal epithelial tissues to prevent entry of SARS-CoV-2 and related viruses, to treat the cytokine storm that precedes and underlies acute respiratory distress syndrome in COVID-19 and other diseases, and to affect viral life cycle processes. In addition, on March 30, 2020, Swysh, Pathway Rx and their research team announced the publication a working paper detailing aspects of the research undertaken to date and outlining anticipated next steps in that process. The paper, entitled In Search of Preventative Strategies: Novel Anti-Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues is available for viewing and study at https://www.preprints.org/manuscript/202004.0315/v1. Further, in April 2020, Pathway Rx and their research team published another research paper entitled Fighting the storm: novel anti- TNF and anti-IL-6 C. sativa lines to tame cytokine storm in COVID-19, available at https://www.researchsquare.com/article/rs-30927/v1.

In commenting on these developments, Dr. Kovalchuk stated: The relationship with our group of companies to AGB has expanded through, first, the InPlanta license agreement, and then the license agreement with Swysh Inc. Now, with what may be the most important and timely element of these developing relationships, this license agreement between AGB and Pathway Rx sets the stage to proceed with clinical trials that may significantly expand and create applications for those significant new varieties of cannabinoid varieties that we have been developing. In this era in which all dimensions of society are affected by the Covid-19 pandemic, we are duty-bound to apply as much of our expertise as possible to mitigate the effects of this disease, and, with the participation of AGB, we intend to do so in a positive way.

About AGB:

AGB is an early stage international bio-technology company focused on the development, evaluation, testing, application and, ultimately, supply to the market of proprietary organic hybridization technology and certain products derived from that technology. The core approach of the business is centred on the planting, growth and harvesting of new and valuable strains of hemp and related crops in commercial quantities under the terms of license agreements with InPlanta Biotechnology Inc., Swysh Inc. and Pathway Rx Inc.

For further information, contact:

David PinkmanChief Executive Officer(403) 863-6034

The Company is not making any express or implied claims that any product produced pursuant to the terms of its license agreements has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronovirus) at this time.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Asia Green Biotechnology Corp.

View source version on accesswire.com:https://www.accesswire.com/602186/Asia-Green-Biotechnology-Corp-Enters-Technology-License-Agreement-with-Pathway-Rx-Inc-for-Asia-Region-and-Agrees-to-Assist-in-Initiating-Clinical-Trials

The rest is here:
Asia Green Biotechnology Corp. Enters Technology License Agreement with Pathway Rx Inc. for Asia Region and Agrees to Assist in Initiating Clinical...

The research, analysis and estimations about the market have been performed with the steadfast knowledge in this Aptamers Market report. This market report helps to obtain information about all the above factors by giving actionable market insights and comprehensive market analysis. Analysis and discussion of important industry trends, market size, sales volume, and market share are also estimated in this market report. To achieve maximum return on investment (ROI), its very fundamental to figure out market parameters such as brand awareness, market landscape, possible future issues, industry trends & customer behaviour where this Aptamers Market report comes into picture.

Request for sample copy or PDF Herehttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-aptamers-market

Global Aptamers Market report gives clear idea to Healthcare industry in regard with what is already available in the market, what market anticipates, the competitive environment, and what to be get done to surpass the competitor. This market report serves a great purpose of better decision making and achieving competitive advantage. The report supports in evaluating brand awareness, market landscape, possible future issues, industry trends and customer behaviour with which refined business strategies can be fixed. Aptamers Market report has been comprised of a significant data along with future forecast and detailed analysis on a global and regional level.

Global Aptamers Marketis expected to rise from its initial estimated value of USD 176.86 million in 2018 to an estimated value of USD 722.69 million by 2026, registering a CAGR of 19.01% in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing R&D investments in biotechnology and pharmaceutical sectors.

Few of the major competitors currently working in the globalaptamers marketareAptamer Sciences, Inc., AMBiotech, Aptagen, LLC., Aptamer Group, Aptus Biotech, Base Pair Biotechnologies, Cambio, NeoVentures Biotechnology Inc., SOMALOGIC, INC., TriLink BioTechnologies, LLC, Vivonics Inc., NOXXON Pharma, 2bind GmbH, NOVAPTECH, Donovan Biotechnology, LLC, ATDBio Ltd., AuramerBio, Barrick Lab, Creative Biogene, AMS Biotechnology (Europe) Limited, IBA GmbH and Kaneka Corporation among others.

Browse Detailed TOC Herehttps://www.databridgemarketresearch.com/toc?dbmr=global-aptamers-market

Market Definition: Global Aptamers Market

Aptamersare single-stranded DNA or RNA (ssDNA or ssRNA) molecules. Aptamers are the oligonucleotide or peptide molecules that bind to a specific target molecule. It assumes to have a variety of shapes due to their tendency to form helices and single-stranded loops. There are many advantages of these small molecules in comparison to the antibodies.

Technology market research report are based upon SWOT analysis on which businesses can rely confidently.

Segmentation: Global Aptamers Market

Aptamers Market : By Type

Aptamers Market : By Application

Aptamers Market : By Technology

Aptamers Market : By End User

Aptamers Market : ByGeography

Key Developments in the Aptamers Market:

Aptamers Market Drivers

Aptamers Market Restraints

Features mentioned in the report

Want Full Report? Enquire Herehttps://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-aptamers-market

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

See more here:
Aptamers Market 2020-2026 to Eyewitness Massive Growth : Leading Key Players NeoVentures Biotechnology Inc., SOMALOGIC, INC., TriLink...

A rating of 96 puts Seres Therapeutics Inc (MCRB) near the top of the Biotechnology industry according to InvestorsObserver. Seres Therapeutics Inc's score of 96 means it scores higher than 96% of stocks in the industry. Seres Therapeutics Inc also received an overall rating of 84, putting it above 84% of all stocks. Biotechnology is ranked 20 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Seres Therapeutics Inc (MCRB) stock is trading at $26.65 as of 1:21 PM on Wednesday, Aug 19, an increase of $2.39, or 9.85% from the previous closing price of $24.26. The stock has traded between $23.84 and $27.78 so far today. Volume today is light. So far 999,797 shares have traded compared to average volume of 5,236,788 shares.

To see the top 5 stocks in Biotechnology click here.

See the original post:
Is Seres Therapeutics Inc (MCRB) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Synlogic Inc (SYBX) is around the middle of the Biotechnology industry according to InvestorsObserver. SYBX received an overall rating of 42, which means that it scores higher than 42 percent of all stocks. Synlogic Inc also achieved a score of 34 in the Biotechnology industry, putting it above 34 percent of Biotechnology stocks. Biotechnology is ranked 18 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 42 means the stock is more attractive than 42 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Synlogic Inc (SYBX) stock is down -0.78% while the S&P 500 is unchanged 0% as of 11:39 AM on Tuesday, Aug 18. SYBX has fallen -$0.02 from the previous closing price of $2.57 on volume of 57,969 shares. Over the past year the S&P 500 is higher by 15.68% while SYBX has fallen -47.20%. SYBX lost -$1.67 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Go here to see the original:
Is Synlogic Inc (SYBX) the Top Pick in the Biotechnology Industry? - InvestorsObserver

CBA will provide high-quality analytical services for biopharmaceutical developers and manufacturers

By PIB Delhi

The Center for Biopharma Analysis (CBA) supported by the National Biopharma Mission (NBM) of Department of Biotechnology (DBT)- Biotechnology Industry Research Assistance Council (BIRAC) at Pune-based technology business incubator, Venture Center was inaugurated virtually by Secretary, DBT, Dr Renu Swarup.

CBA will provide high-quality analytical services for biopharmaceutical developers and manufacturers. This center is envisioned to become a resource center for structural and functional characterization of biologicals and biopharmaceuticals that will create long lasting value for bioentrepreneurs and industry.

Inaugurating the facility via video conference, Dr Renu Swarup, Secretary, DBT, said that she expects that the CBA will play a pivotal role in supporting biopharma innovations from academic and government research labs, startups and many Indian companies with not only high-quality analytical characterization but also advise on studies needed for regulatory approvals. This can help speed up the development process.

Also speaking on the occasion, Prof AK Nangia, Director, CSIR-NCL highlighted how NCL is keen to contribute to the large molecule therapeutics revolution waiting to happen in India as it did for small molecule therapeutics in 1970-80s. Mr Prasanta Biswal, CEO of International Biotech Park Limited, Pune said that IBPL is happy to have contributed CSR support for the CBA infrastructure development and looks forward to working closely with Venture Center and BIRAC in positioning the Pune Knowledge Cluster for excellence in biopharma and medtech development and manufacturing.

About DBT:The Department of Biotechnology (DBT), under the Ministry of Science & Technology, promotes and accelerates the development of biotechnology in India, including growth and application of biotechnology in the areas of agriculture, healthcare, animal sciences, environment and industry.

About BIRAC:Biotechnology Industry Research Assistance Council (BIRAC) is a not-for-profit Section 8, Schedule B, Public Sector Enterprise, set up by Department of Biotechnology (DBT), Government of India as an Interface Agency to strengthen and empower the emerging Biotech enterprise to undertake strategic research and innovation, addressing nationally relevant product development needs

About National Biopharma Mission:The Industry-Academia Collaborative Mission of Department of Biotechnology (DBT), Govt of India for accelerating discovery research to early development for Biopharmaceuticals approved by the Cabinet for a total cost US$ 250 million and 50% co-funded by the World Bank is being implemented at Biotechnology Research Assistance Council (BIRAC). This program is dedicated to deliver affordable products to the nation with an aim to improve the health standards of Indias population. Vaccines, medical devices and diagnostics and biotherapeutics are few of its most important domains, besides, strengthening the clinical trial capacity and building technology transfer capabilities in the country.

About Venture Center:Entrepreneurship Development Center (Venture Center) a CSIR initiative is a Section 25 company hosted by the National Chemical Laboratory, Pune. Venture Center strives to nucleate and nurture technology and knowledge-based enterprises by leveraging the scientific and engineering competencies of the institutions in the Pune region in India. The Venture Center is a technology business incubator supported by the Department of Science & Technologys National Science & Technology Entrepreneurship Development Board (DST-NSTEDB). Venture Center focuses on technology enterprises offering products and services exploiting scientific expertise in the areas of materials, chemicals and biological sciences & engineering. For more information, visit:http://www.venturecenter.co.in/

About CBA:Center for BioPharma Analysis (CBA) is an initiative of Venture Center supported by the National BioPharma Mission, BIRAC (Government of India). The Venture Center is a technology business incubator hosted by CSIR-National Chemical Laboratory, Pune. It is a state-of-art GLP compliant facility with high-end instrumentation and industry-linked personals provides globally acceptable analysis of biopharmaceuticals. It provides open access cutting-edge technologies for Biopharmaceutical Analysis and would emerge as resource center for Characterization of Biopharmaceuticals. The facility aims to cater all academics, small to medium size biosimilar developers through-out the India and the world. For more information, visit:https://www.venturecenter.co.in/biopharma/

For Further Information: Contact Communication Cell of DBT/BIRAC

http://www.dbtindia.gov.inwww.birac.nic.in

Read this article:
Department of Biotechnology supported National Facility at Venture Center, Pune now open for operations - IBG NEWS

SEATTLE, July 8, 2020 /PRNewswire/ --Seattle's AVM Biotechnology, an up-and-coming biotech firm whose lead molecule, AVM0703, has received FDA permission to begin clinical trials treating no-option Non-Hodgkin's Lymphoma and is applying to begin trials treating moderate-severely ill COVID-19 patients, announced today the hiring of Janet R. Rea, MSPH, as Chief Operating Officer. As COO, Rea will lead operations and direct regulatory affairs as the company conducts clinical trials and brings AVM0703 to market.

"I am delighted that Janet Rea will join our team at AVM Biotechnology as the Chief Operating Officer. Having worked with Janet during a pivotal time at Protein Sciences while pursuing Flublok FDA approval," said Dr. Manon Cox, AVM Biotechnology's Executive Board Member, "I know that her passion for quality and her tremendousexperience in the transition from development into commercialization is exactly what we need at this crucial time at AVM now that our lead product is moving into the clinic."

Janet R. Rea, MSPH, RAC, brings over 35 years of industry leadership experience in clinical development through commercialization in biologics and small molecules, with focus on oncology, infectious diseases, orphan and rare diseases. She obtained her B.S. in microbiology and M.S. in Public Health from the University of Washington. Her career in the healthcare industry began with then-American Hospital Supply Corporation (now Baxter), followed by Genetic Systems. Ms. Rea was an early employee of Seattle-based Immunex Corporation, where she played a key role in the company's first licensed product, Leukine. She held positions with increasing levels of responsibility with MDS Pharma and Targeted Genetics, as well as executive positions with AVI BioPharma (now Sarepta), Poniard Pharmaceuticals and Protein Sciences Corporation (acquired by Sanofi), and Therapeutic Proteins International. Most recently, she was SVP of Regulatory, Quality and Clinical Affairs at Atossa Therapeutics (Genetics) with focus on breast cancer and COVID-19 therapy development. She has also operated a consulting practice to both small and large organizations and has lectured at the University of Washington for the Biomedical Regulatory Affairs Certificate and Master's Program, where she also served as a parttime Assistant Clinical Professor for two years.Ms. Rea will serve as a non-voting member of AVM's Board of Directors.

"I am thrilled and honored to be joining AVM Biotechnology and look forward to working with this distinguished team to make new therapies available," Ms. Rea said. Named one of the "10 Best Biotech & Pharma Companies to Keep an Eye On in 2019" by Mirror Review, AVM Biotechnology was founded in 2008 by Dr. Theresa Deisher, Ph.D. With over 30 years of successful pharmaceutical research experience and holding over 47 patents, Dr. Deisher leads a team of scientists dedicated to changing the meaning of a diagnosis of cancer, autoimmunity, or chronic infectious disease for patients and their loved ones. In April 2020, AVM received FDA permission to begin clinical trials to test its lead molecule AVM0703 for treatment of relapsed/refractory lymphoid malignancies, and is filing for FDA approval to begin clinical trials in treating COVID-19 and influenza induced ARDS. AVM's passion is to deliver drugs that work rapidly and that are safe, effective, and affordable to treat serious worldwide illnesses such as cancer, autoimmunity, and life-altering infectious disease. AVM develops products that improve outcomes without additional suffering because side effects from treatments of cancers or infections should never be worse than the diseases themselves. The addition of Janet Rea to the AVM team, which includes a global group of experienced biotech advisors, makes AVM well positioned to bring AVM0703 to market in treating multiple conditions.

Contact Jena Dalpez Jdalpez@AVMBiotech.com

ALL INFORMATION CONTAINED HEREIN HAS BEEN PROVIDED BY THE COMPANY AND NO OTHER PARTY HAS INDEPENDENTLY VERIFIED ANY OF THE INFORMATION, INCLUDING THE FINANCIAL ESTIMATES AND PROJECTIONS CONTAINED HEREIN. SOME OF THE STATEMENTS IN THE MEMORANDUM ARE "FORWARD-LOOKING STATEMENTS." THESE FORWARD-LOOKING STATEMENTS INCLUDE, BUT ARE NOT LIMITED TO, STATEMENTS ABOUT THE COMPANY'S PLANS, OBJECTIVES, EXPECTATIONS AND INTENTIONS AND OTHER STATEMENTS CONTAINED IN THE MEMORANDUM THAT ARE NOT HISTORICAL FACTS. WHEN USED IN THIS MEMORANDUM, THE WORDS "ASSUMES," "ANTICIPATES," "BELIEVES," "CONTINUE," "COULD," "EXPECTS," "FORECASTS," "INTENDS," "MAY," "PLANS," "SEEKS," "SHOULD," OR "WILL" OR THE NEGATIVE OF THESE TERMS OR SIMILAR EXPRESSIONS ARE GENERALLY INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. BECAUSE THESE FORWARD-LOOKING STATEMENTS INVOLVE RISKS AND UNCERTAINTIES, THERE ARE IMPORTANT FACTORS THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE EXPRESSED OR IMPLIED BY THESE FORWARD-LOOKING STATEMENTS, INCLUDING THE COMPANY'S PLANS, OBJECTIVES, EXPECTATIONS AND INTENTIONS AND OTHER FACTORS DISCUSSED UNDER "RISK FACTORS" SUCH STATEMENTS, ESTIMATES AND PROJECTIONS REFLECT VARIOUS ASSUMPTIONS OF THE COMPANY THAT MAY OR MAY NOT PROVE TO BE CORRECT. AND NO REPRESENTATION IS MADE AND NO ASSURANCE CAN BE GIVEN THAT THE COMPANY CAN OR WILL ATTAIN SUCH RESULTS.

See the rest here:
AVM Biotechnology Expands Executive Team in Preparation for Oncology & COVID-19 Clinical Trials, Appoints Janet R. Rea, MSPH, Chief Operating...

Biotechnologys game-changing role as a catalyst to reboot the economy and build a more sustainable future will be the focus of a summit co-hosted by The University of Manchester.

The panel debate and live Q&A is entitled Biotechnology: The Catalyst for a Sustainable Future and will feature leading experts from the prestigious Manchester Institute of Biotechnology who will be joined by national policy-makers and influencers.

The virtual event will be held on Wednesday, July 15, 3-4pm and the discussion will coincide with a special Spotlight supplement focusing on the UKs world-leading biotechnology capability to be published in the latest edition of the New Statesman. Hosted in partnership with the magazine the expert panel will be made up of:

George Freeman, MP, and former Minister of Life Sciences

Professor Rob Field, Director of the Manchester Institute of Biotechnology

Yvonne Armitage Chair of the External Advisory Board for Future Biomanufacturing Research

Professor Lionel Clarke OBE, Co-Chair of the UK Engineering Biology Leadership Council

Industrial Biotechnology (IB) is the term that describes the application of natures catalysts ie enzymes and other biological systems to sustainably produce chemicals, materials and energy says Professor Rob Field, Director of the Manchester Institute of Biotechnology (MIB).

Using the latest developments in biotechnology, and by collaborating with industry, it will be possible to produce medicines, plastics and fuels that are not are not sourced from carbon-generating fossil fuels.

Themes that will be put under the spotlight at the live streamed debate will include the potential capability of biotechnology to meet the global grand challenges and how might the COVID-19 crisis act as a catalyst to accelerate the adoption of biotechnology by society.

Sustainable development is one of the biggest challenges facing society and industry today as we look to meet todays energy, food and manufacturing needs without exhausting the Earths resources, explained Professor Field.

Biotechnology could provide the catalyst for revolutionary change and help us build a better more sustainable future.

COVID-19 has shown science at its best agile yet focused, collaborative while competitive. We can learn from the experience to develop a more resilient and sustainable world. Biotechnology has a large part to play in supporting a clean growth recovery.

Our panel discussion and the special edition of the New Statesmans Spotlight which supports this talk will reveal just of how biotechnology could help support a sustainable re-booting of the economy.

Register to tune in to this online event at 3pm on Wednesday, July 15, and receive joining information closer to the date. Spaces are available on a first come, first serve basis. Registration details here: https://www.newstatesman.com/2020/06/new-statesman-and-mib-webinar-biotechnology-catalyst-sustainable-future

###

Read the original here:
Could biotechnology be the vital catalyst to deliver a green economic recovery? (Study) - Tdnews

Akero Therapeutics Inc (AKRO) is around the top of the Biotechnology industry according to InvestorsObserver. AKRO received an overall rating of 69, which means that it scores higher than 69 percent of all stocks. Akero Therapeutics Inc also achieved a score of 78 in the Biotechnology industry, putting it above 78 percent of Biotechnology stocks. Biotechnology is ranked 11 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Akero Therapeutics Inc (AKRO) stock is trading at $37.79 as of 10:20 AM on Wednesday, Jul 8, a rise of $0.73, or 1.97% from the previous closing price of $37.06. The stock has traded between $37.61 and $41.00 so far today. Volume today is above average. So far 607,617 shares have traded compared to average volume of 380,338 shares.

To screen for more stocks like AKRO click here.

Read the original post:
Is Akero Therapeutics Inc (AKRO) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver